|1.||Krieg, Arthur M: 4 articles (05/2006 - 05/2003)|
|2.||Bhattacharya-Chatterjee, Malaya: 3 articles (02/2009 - 05/2003)|
|3.||Saha, Asim: 3 articles (02/2009 - 05/2003)|
|4.||Chatterjee, Sunil K: 3 articles (02/2009 - 05/2003)|
|5.||Foon, Kenneth A: 3 articles (02/2009 - 05/2003)|
|6.||Chen, Wei: 2 articles (01/2013 - 04/2011)|
|7.||Qiao, Tiankui: 2 articles (01/2013 - 04/2011)|
|8.||Yuan, Sujuan: 2 articles (01/2013 - 04/2011)|
|9.||Weiner, George J: 2 articles (05/2006 - 05/2003)|
|10.||Baral, Rathindra Nath: 2 articles (05/2006 - 05/2003)|
05/01/2006 - "In this study, we have evaluated the efficacy of 3H1 as a tumor vaccine when admixed with a select CpG ODN 1826 in transgenic mice that express human CEA. "
04/01/2011 - "First, tumor growth delay was observed, and the enhancement ratio of CpG ODN 1826 was found to be 2.4; decreased tumor weight was found after combined treatments with CpG ODN 1826 and X-ray radiation compared with either treatment alone (P < 0.01). "
02/15/2009 - "The systemic administration of CpG ODN 1826 alone had modest effect on tumor growth when tumors were palpable and had no effect with larger tumor burden. "
10/01/2007 - "To investigate the anti-tumor and side effect of CpG ODN 1826 and CpG ODN2006 as an adjuvants on leukemic tumor in mouse-models, an acute lymphocytic leukemic tumor in mouse model was established, then inoculated inactivated L1210 cells alone or with different vaccine adjuvants were injected subcutaneously into each DBA/2 model mouse at different times. "
08/01/2006 - "Treatment with CpG ODN 1826 resulted in strongly enhanced response of FSa tumors to radiation and MCa-K tumors to the chemotherapeutic agent DOC. "
|2.||Lung Neoplasms (Lung Cancer)
01/01/2013 - "This study aimed to define the dose-effect relationship for CpG ODN 1826 in increasing radiosensitivity and its impact on immune function in a mouse model of Lewis lung cancer. "
01/01/2015 - "CpG ODN 1826 enhances radiosensitivity of the human lung cancer cell line A549 in a rat model."
04/01/2011 - "The present study extended this finding to the fractionated radiotherapy of the Lewis lung cancer and assessed the ability of CpG ODN 1826 to increase the immune function of mice and the effect of CpG ODN 1826 on the apoptosis of Lewis lung cancer. "
01/01/2013 - "With the increasing concentration of CpG ODN 1826, its effect became more and more significant, meanwhile, inoculation of Lewis lung cancer cells failed in those CpG ODN-cured mice. "
10/01/2007 - "In this study, we have attempted to determine whether the systemic administration of CpG oligodeoxynucleotide (CpG-ODN) 1826 would protect mice against systemic lethal Candida albicans infection. "
03/01/2001 - "Treatment of mice with CpG ODN 1826 (TCCATGACGTTCCTGACGTT, with the CpG dinucleotides underlined) or 1585 (ggGGTCAACGTTGAgggggG, with g representing diester linkages and phosphorothioate linkages being to the right of lowercase letters) in the absence of antigen 1 to 2 days prior to challenge with Plasmodium yoelii sporozoites conferred sterile protection against infection. "
01/01/2014 - "Taken together, it's revealed that recombinant DNA vaccine pIRES-toxAm-pcrV was a potential candidate for immunotherapy of Pseudomonas aeruginosa infection and the CpG ODN 1826 a potent stimulatory adjuvant for DNA vaccination. "
02/01/2004 - "The adjuvant effect of CpG ODN 1826 was manifested as both significantly improved complete protection from malaria (defined as the absence of detectable erythrocytic form parasites) (P = 0.007, chi square) and reduced parasite burden in infected mice. "
02/01/2004 - "We determined the adjuvant effect of murine CpG ODN 1826 on the immunogenicity and protective efficacy of the Saccharomyces cerevisiae-expressed 19-kDa C-terminal region of merozoite surface protein 1 (yMSP1(19)) of the murine malaria parasite Plasmodium yoelii. "
02/01/2004 - "We found that in C57BL/6 mice, following sporozoite challenge, the degree of protective immunity against malaria induced by yMSP1(19) in a formulation of Montanide ISA 51 (ISA) plus CpG ODN 1826 was similar or superior to that conferred by yMSP1(19) emulsified in complete Freund's adjuvant (CFA/incomplete Freund's adjuvant). "
05/01/2003 - "In this study, using the CEA-transduced MC-38 murine colon carcinoma model in syngeneic C57BL/6 mice, we assessed whether a select CpG ODN (1826) can function as immune adjuvant in immunization of mice with anti-Id 3H1. "
08/01/2006 - "Using two immunogenic murine tumors, a fibrosarcoma (FSa) and a mammary carcinoma (MCa-K), the present study explored whether CpG ODN 1826 also improves the response of murine tumors to the chemotherapeutic agent docetaxel (DOC). "
|2.||Merozoite Surface Protein 1 (MSA1)
|8.||Recombinant DNA (Recombinant DNA Research)
|9.||DNA (Deoxyribonucleic Acid)
|10.||montanide ISA 51
|5.||Drug Therapy (Chemotherapy)